Biosynth

Biosynth Expands Berlin Site with a New Commercial Bioconjugation Suite

The new suite extends GMP bioconjugate production for intermediates and active pharmaceutical ingredients from early clinical phase through to late clinical phases and commercial supply 3 July 2025 -- Staad, Switzerland -- Biosynth, a leading developer and supplier of critical raw materials and services for life sciences and diagnostics, is pleased to announce the opening...

Biosynth’s Unique Online Custom Peptide Toolset Completed with Full Order Tracking and QC Data Portal

Automated custom peptide quotations and tracking for web account holders - simplifying the process, increasing transparency and reducing process delays 26 June 2024 -- Staad, Switzerland -- Biosynth, a supplier of critical raw materials and services for diagnostics, vaccines and pharmaceuticals, is pleased to announce the next step in its custom peptide revolution. In October,...

Biosynth to offer complex chemistry solutions at greater scales following acquisition of VIO Chemicals

Expansion of capacity for reliable, sustainable, and flexible manufacturing solutions at any production scale. 19 December 2023 – Biosynth, a supplier of critical raw materials to the life science industry, is pleased to announce today that it has acquired VIO Chemicals, a Zurich-based company with leading chemical R&D expertise and a global network of large-scale...
Rietlistr. 4 Staad, St. Gallen 9422, CH

+44 (0)1635 578444